VistaGen reports positive fasedienol data in PALISADE-3 open-label extension study

Vistagen

Vistagen

VTGN

0.00
  • VistaGen reported preliminary positive data already released from ongoing open-label extension of PALISADE-3 Phase 3 study of fasedienol nasal spray for acute treatment of social anxiety disorder.
  • Interim readout showed fasedienol remained generally well tolerated with no new drug-related safety issues during as-needed use in daily life for up to 12 months.
  • Exploratory assessments indicated social anxiety symptoms eased over time across clinician-rated and patient-reported measures during first four months of treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605120730BIZWIRE_USPR_____20260512_BW521110) on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.